Last reviewed · How we verify
Amvuttra (VUTRISIRAN)
Amvuttra works by silencing the production of abnormal TTR protein through RNA interference.
At a glance
| Generic name | VUTRISIRAN |
|---|---|
| Sponsor | Alnylam Pharmaceuticals |
| Drug class | Small Interfering RNA |
| Target | transthyretin (TTR) mRNA |
| Modality | Oligonucleotide |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2022 |
| Annual revenue | 1100 |
Mechanism of action
Vutrisiran is double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in reduction of serum TTR protein and TTR protein deposits in tissues.
Approved indications
- Transthyretin familial amyloid polyneuropathy
Common side effects
- Arthralgia
- Dyspnea
- Vitamin decreased
- Atrioventricular (AV) heart block
- Injection site reactions
- Anti-drug antibodies
- Bruising
- Erythema
- Pain
- Pruritus
- Warmth
Key clinical trials
- APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis (PHASE3)
- A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (PHASE3)
- TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (PHASE3)
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (PHASE3)
- HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) (PHASE3)
- Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
- Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR (PHASE2)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amvuttra CI brief — competitive landscape report
- Amvuttra updates RSS · CI watch RSS
- Alnylam Pharmaceuticals portfolio CI